Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double Blind, Placebo Controlled, Parallel Group, Multicenter Study to Investigate the Efficacy and Safety of SER120 Nasal Spray Formulations in Patients With Nocturia

NCT01357356 is registered in ClinicalTrials.gov with Serenity Pharmaceuticals, Inc. as lead sponsor.

NCT NCT01357356
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01357356 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double Blind, Placebo Controlled, Parallel Group, Multicenter Study to Investigate the Efficacy and Safety of SER120 Nasal Spray Formulations in Patients With Nocturia
Lead sponsor
Serenity Pharmaceuticals, Inc.
Phase
Phase 2/3
Overall status
Completed
Start date
May 31, 2011
Completion date
December 31, 2014
Enrollment
750 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

nocturia